Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Find beginner-friendly options with understandable use cases and liquidity, plus a simple framework to compare potential investments.
27,615 articlesIn the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
The idea of an ETF hitting the $1 trillion milestone sounds like fantasy, but it’s worth understanding what it would ...
A bold $1.5 billion investment signals Boston Scientific’s shift into transcatheter aortic valve replacement. Explore...
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
When geopolitics roils markets, the duration of the shock matters most. This week, investors should focus on how long...
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...
Micron just posted standout results, fueling chatter about a potential stock split. This guide breaks down what a spl...
Rising oil prices amid escalating tensions weigh on the Dow and broader U.S. markets. This guide breaks down why ener...
Vanguard’s FTSE Emerging Markets ETF (VWO) omits South Korea due to a 2009 reclassification, leaving investors expose...
Two sector income ETFs are delivering yields well above the S&P 500 as investors price in a possible recession. The g...
Two popular tech ETFs sit on opposite ends of the spectrum: a broad technology exposure semiconductor approach with V...
Rivian shares jumped about 8% amid a crucial R2 production debut and rising software revenue, even as peers Tesla and...